These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2727475)

  • 21. Estimators of the local false discovery rate designed for small numbers of tests.
    Padilla M; Bickel DR
    Stat Appl Genet Mol Biol; 2012 Oct; 11(5):4. PubMed ID: 23079518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An MSE-reduced estimator for the response proportion in a two-stage clinical trial.
    Li Q
    Pharm Stat; 2011; 10(3):277-9. PubMed ID: 20140880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimation of a secondary parameter in a group sequential clinical trial.
    Gorfine M
    Biometrics; 2001 Jun; 57(2):589-97. PubMed ID: 11414589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minimax Estimation of Functionals of Discrete Distributions.
    Jiao J; Venkat K; Han Y; Weissman T
    IEEE Trans Inf Theory; 2015 May; 61(5):2835-2885. PubMed ID: 29375152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generalizing boundaries for triangular designs, and efficacy estimation at extended follow-ups.
    Allison A; Edwards T; Omollo R; Alves F; Magirr D; E Alexander ND
    Trials; 2015 Nov; 16():522. PubMed ID: 26573827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimating the mean value of occupational exposures.
    Zhou XH
    Am Ind Hyg Assoc J; 1998 Nov; 59(11):785-8. PubMed ID: 9830086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Computation of the uniform minimum variance unbiased estimator of a normal mean following a group sequential trial.
    Emerson SS
    Comput Biomed Res; 1993 Feb; 26(1):68-73. PubMed ID: 8444028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blinded sample size re-estimation in superiority and noninferiority trials: bias versus variance in variance estimation.
    Friede T; Kieser M
    Pharm Stat; 2013; 12(3):141-6. PubMed ID: 23509095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blinded sample size re-estimation in three-arm trials with 'gold standard' design.
    Mütze T; Friede T
    Stat Med; 2017 Oct; 36(23):3636-3653. PubMed ID: 28608469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simple efficient bias corrected instrumental variable estimator for randomized trials with noncompliance.
    Chan KC
    Contemp Clin Trials; 2012 Jul; 33(4):786-93. PubMed ID: 22484340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calibrated phase II clinical trials in oncology.
    Herson J; Carter SK
    Stat Med; 1986; 5(5):441-7. PubMed ID: 3786998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A sequential phase II/III trial for binary outcomes.
    Storer BE
    Stat Med; 1990 Mar; 9(3):229-35. PubMed ID: 2160719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimation of direct formulation effect under log-normal distribution in bioavailability/bioequivalence studies.
    Liu JP; Weng CS
    Stat Med; 1992 May; 11(7):881-96. PubMed ID: 1604068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuous and group sequential conditional probability ratio tests for phase II clinical trials.
    Tan M; Xiong X
    Stat Med; 1996 Oct; 15(19):2037-51. PubMed ID: 8896138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bias-corrected maximum likelihood estimator of the intraclass correlation parameter for binary data.
    Saha KK; Paul SR
    Stat Med; 2005 Nov; 24(22):3497-512. PubMed ID: 16007569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Planned versus attained design in phase II clinical trials.
    Green SJ; Dahlberg S
    Stat Med; 1992 May; 11(7):853-62. PubMed ID: 1604065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bias-corrected estimator for intraclass correlation coefficient in the balanced one-way random effects model.
    Atenafu EG; Hamid JS; To T; Willan AR; Feldman BM; Beyene J
    BMC Med Res Methodol; 2012 Aug; 12():126. PubMed ID: 22905752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interval estimation of the attributable risk in case-control studies with matched pairs.
    Lui KJ
    J Epidemiol Community Health; 2001 Dec; 55(12):885-90. PubMed ID: 11707482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Designs for group sequential phase II clinical trials.
    Chang MN; Therneau TM; Wieand HS; Cha SS
    Biometrics; 1987 Dec; 43(4):865-74. PubMed ID: 3427171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. On the multiple imputation variance estimator for control-based and delta-adjusted pattern mixture models.
    Tang Y
    Biometrics; 2017 Dec; 73(4):1379-1387. PubMed ID: 28407203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.